Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts. Show more
Location: 321 Summer Street, Boston, MA, 02210, United States | Website: https://www.inozyme.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
257.6M
52 Wk Range
$0.72 - $6.24
Previous Close
$3.99
Open
$4.00
Volume
1,457,159
Day Range
$3.99 - $4.00
Enterprise Value
219.8M
Cash
84.78M
Avg Qtr Burn
-24.13M
Insider Ownership
1.23%
Institutional Own.
96.26%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
INZ-701 (ENPP1-Fc) Details ENPP1 deficiency, Genetic disorder, Rare genetic disease | Phase 3 Data readout | |
INZ-701 (ENPP1-Fc) Details ENPP1 deficiency, Genetic disorder, Rare genetic disease, ABCC6 Deficiency | Phase 1/2 Update | |
INZ-701 (ENPP1-Fc) Details ENPP1 deficiency, Genetic disorder, Rare genetic disease | Phase 1b Update | |
INZ-701 (ENPP1-Fc) Details End-stage renal disease | Phase 1 Update |